Poly（ADP-ribose） polymerase inhibitors as promising ：ancer therapeutics

The year of 2005 was a watershed in the history of poly（ADP-ribose） polymerase （PARP） inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new thera- peutic approaches to cancers, espec...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica no. 9; pp. 1172 - 1180
Main Author Jin-xue HE Chun-hao YANG Ze-hong MIAO
Format Journal Article
LanguageEnglish
Published 2010
Subjects
ADP
PARP抑制剂
基因缺陷
癌症治疗
聚合酶
酶抑制剂
Online AccessGet full text

Cover

More Information
Summary:The year of 2005 was a watershed in the history of poly（ADP-ribose） polymerase （PARP） inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new thera- peutic approaches to cancers, especially to those with specific defects. With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.
Bibliography:BRCA1/2
homologous recombination
poly（ADP-ribose） polymerase inhibitor; DNA repair; BRCA1/2; anticancer agents; homologous recombination
Q591.8
TQ465.92
poly（ADP-ribose） polymerase inhibitor
DNA repair
anticancer agents
31-1347/R
ISSN:1671-4083
1745-7254